Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Thrombolytic Therapy for Non-arteritic Central Retinal Artery Occlusion in an Academic Multi-site Stroke Center
Cerebrovascular Disease and Interventional Neurology
S45 - Cerebrovascular Disease and Interventional Neurology: Meta-analyses and Outcomes Research (2:48 PM-3:00 PM)

CRAO is a subtype of acute ischemic stroke leading to severe visual loss. Conventional management is not effective and potentially harmful. 2021 American Heart Association scientific statement proposes similar time-windows for thrombolysis in CRAO and cerebral strokes (4.5hours for IVT, 6hours for IAT).

To review our academic multi-site stroke center experience with intravenous (IVT) and intra-arterial thrombolysis (IAT) for central retinal artery occlusion (CRAO).

We retrospectively identified consecutive CRAO patients that received IVT or IAT in our academic enterprise stroke centers (1997-2022). Demographic, clinical characteristics, thrombolysis timeline, concurrent CRAO therapies, hospital complications, and follow-up visual outcomes were collected and analyzed using descriptive statistics.

Of 563 CRAO admissions, 20 (3.55%) received thrombolytic therapy: 13 IVT (mean age 68, range 55-82, 61.5% male, 12 alteplase and 1 tenecteplase, all embolic etiology) and 7 IAT (mean age 55, range 17-83, 85.7% male, 4 post-operative and 3 embolic). 11/20 (55%) received additional therapies (ocular massage, intraocular pressure lowering drops, diuretics, intra-arterial verapamil). 1 CRAO mimic received IVT. Median visual loss to IVT was 158 minutes (range 67-260 min). Baseline mean logMAR visual acuity (VA) was -3.11 (±1.16). 8/13 IVT had 3-month follow-up VA recorded (mean VA -2.53). 50% improved at least one Snellen line, 12.5% had VA > 20/100. 1/13 (7.6%) had intracranial hemorrhage after IVT. Median visual loss to IAT was 335 minutes (131 minutes to 20 hours). Dose range was 5-30 mg. Baseline IAT mean logMAR VA was -3.5 (±1.19). 5/7 showed VA improvement. 1/7 had profuse epistaxis after IAT.

The management of acute CRAO in a multi-site academic stroke center remains heterogeneous, consultant specific. Most received a combination of thrombolytic and other conventional therapies, hence thrombolysis-specific outcomes could not be described. Prospective studies comparing thrombolysis and placebo are warranted to guide hyperacute CRAO practice.

Jacob Matthew Sobczak
Mr. Sobczak has nothing to disclose.
Nour Sami Ahmad Alhayek, MD (Mayo Clinic) Dr. Alhayek has nothing to disclose.
Emilie Weinberg, Other Miss Weinberg has nothing to disclose.
Bart M. Demaerschalk, MD, MSc, FRCPC, FAAN (Mayo Clinic) Dr. Demaerschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Demaerschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Demaerschalk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Neurologist . The institution of Dr. Demaerschalk has received research support from NICHD.
Oana Maria Dumitrascu, MD (Mayo Clinic) Dr. Dumitrascu has nothing to disclose.